Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Skin biopsy study aims to unlock Vitiligo's repigmentation mystery

NCT ID NCT06068218

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares skin samples from 20 people with vitiligo and 20 healthy volunteers to understand why certain body areas (like the face) repigment well while others (like hands and feet) do not. Researchers will analyze gene activity in skin from five different body sites. The goal is to identify factors that help or hinder repigmentation, which could guide future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal why certain body areas repigment better, pointing toward more targeted treatments for vitiligo.
What could go wrong
This is a small, observational study with only 20 participants. It aims to understand biology, not test a treatment, so direct patient benefits are far off.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Jun 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women with non-segmental vitiligo for the vitiligo group and men and women without any auto-immune disorder for the control group * ≥ 18 and \<70 years * For women of child-bearing age, a urine pregnancy test (βHCG in urines) will be performed. * Affiliation to a social security system * Signed informed consent Exclusion Criteria: * Pregnant women * Segmental or mixed vitiligo * Vitiligo with less than 2 years duration * Skin auto-immune or inflammatory skin disorders other than vitiligo (ie. active atopic dermatitis, psoriasis, lichen planus…) * Exposure to sun (with intent to tan or repigment the skin) or artificial UV (UV cabins, lamps or lasers) during the month before inclusion * Concomitant use of topical or systemic immunosuppressive medication or steroids * Contra-indication to xylocaine with 2 % adrenalin * Pregnant or breast-feeding women * Vulnerable people: minors, adult under guardianship or deprived of freedom, adult under curatorship * Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vitiligo

Contacts and locations

Locations

  • CHU de Nice - Hôpital de l'Archet

    Nice, Alpes-maritimes, 06200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.